SCHEMBL23945672

SCHEMBL23945672

CCC(C)OCC(=O)NCCCCCCCCCCCNC(=O)C(C)(C)CC

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.40
EPHX1 P07099 5/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
CASP2 P42575 1/20 0.35
RIPK1 Q13546 1/20 0.33
NAAA Q02083 1/20 0.33
EPHX2 P34913 1/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
S1PR2 O95136 2/20 0.32
S1PR1 P21453 2/20 0.32
S1PR3 Q99500 2/20 0.32
S1PR5 Q9H228 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19527200 0.81 FAAH (0.45) FAAHEPHX1MEN1KMT2ADRD2
SCHEMBL24673243 0.78 FAAH (0.43) FAAHEPHX1MEN1KMT2ACASP2
SCHEMBL14134865 0.78 EPHX1 (0.53) EPHX1MEN1KMT2ADRD2DRD4
SCHEMBL4546721 0.78 EPHX1 (0.53) EPHX1MEN1KMT2ADRD2DRD4
SCHEMBL13450761 0.76 EPHX1 (0.50) EPHX1MEN1KMT2ADRD2DRD4
SCHEMBL14489334 0.76 RIPK1 (0.40) DRD2DRD4RIPK1
SCHEMBL23945679 0.75 FAAH (0.41) FAAHEPHX1MEN1KMT2ADRD2
SCHEMBL23560051 0.75 KMT2A (0.40) FAAHMEN1KMT2ACASP2ALDH1A1
SCHEMBL26707238 0.75 FAAH (0.41) FAAHEPHX1MEN1KMT2ADRD2
SCHEMBL10093697 0.75 EPHX1 (0.45) EPHX1MEN1KMT2ADRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 FAAH 1771/4885EPHX1 1684/4885MEN1 4055/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 FAAH 1771/4885EPHX1 1684/4885MEN1 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.